Endurance training for patients with sickle cell disease
Evaluation of a Long-term Endurance Training Program in Patients With Sickle Cell Disease: Benefits on Clinical Profile, Physical Fitness and Quality of Life of Patients
This study is testing whether a long-term endurance training program can help improve health, fitness, and quality of life for both adults and children with sickle cell disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Créteil) |
| Trial ID | NCT06823219 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of a long-term endurance training program on patients with sickle cell disease (SCD), focusing on improvements in clinical profile, physical fitness, and quality of life. It aims to include a diverse cohort of both adult and pediatric patients, particularly those with complications, over a one-year period. The study builds on previous findings that moderate-intensity endurance training can be safe and beneficial for SCD patients, with the primary outcome being enhanced physical ability. Participants will undergo a structured training regimen designed to improve their overall health and fitness levels.
Who should consider this trial
Good fit: Ideal candidates are individuals aged over 15 years with a confirmed diagnosis of sickle cell disease who are in a stabilized condition.
Not a fit: Patients who are already engaged in regular physical activity or have unresolved chronic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly enhance the physical fitness and quality of life for patients with sickle cell disease.
How similar studies have performed: Previous studies have shown positive outcomes with endurance training in sickle cell disease, indicating that this approach is promising and not entirely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged over 15 years and 3 months * Male or female * Patients with sickle cell disease (HbSS or HbS-βthal0) * Affiliated to a social security system * Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved * Patients in stabilised condition at the start of the experiment: at least 1 month after an acute chronic event or at least 3 months after a blood transfusion. * Patients hospitalised for vaso-occlusive crisis at least once in the last 3 years Exclusion Criteria: * Patient whose adherence to the protocol is unlikely according to the investigator * Patients who already partake in regular physical activity (more than 1 hour of moderate-intensity physical activity per week) * Patients with a chronic inflammatory and/or infectious pathology * Patients with an intercurrent condition unresolved for less than a month * Patients hospitalised for cardiac decompensation during the last 12 months * Patients on anticoagulant treatment or with a pacemaker/defibrillator * Pregnant patients / breastfeeding woman * Patients deprived of liberty by judicial or administrative decision or patient under guardianship * Patients unable to understand the objectives and conditions of the study and unable to give cons
Where this trial is running
Créteil
- Henri Mondor Hospital — Créteil, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.